• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

双 XEN 45 凝胶支架植入治疗严重青光眼性高眼压的理论科学依据。

Theoretic scientific rationale of double XEN 45 Gel Stent implant in severe glaucomatous ocular hypertension.

机构信息

Ophthalmic Unit, San Bassiano Hospital, Bassano del Grappa, Italy.

Eye Clinic, Department of Neuroscience, Biomedicine and Mouvement, University of Verona, Verona, Italy.

出版信息

Int Ophthalmol. 2023 May;43(5):1629-1638. doi: 10.1007/s10792-022-02561-6. Epub 2022 Oct 29.

DOI:10.1007/s10792-022-02561-6
PMID:36308577
Abstract

PURPOSE

To investigate the theoretical hydrodynamic effects of a single or a double XEN 45 Gel Stent (XEN45) implant in glaucomatous eyes.

METHODS

A prospective non-randomized clinical study on 63 glaucomatous eyes of 63 patients. The preoperative intraocular pressure (IOP) values after 14 days of medical therapy washout was correlated to the postoperative IOP values 7 and 45 days after the implant of a XEN45. A mathematical model based on the Hagen-Poiseuille law was designed to assess the residual aqueous humor outflow (AHO) facility in glaucomatous eyes in function of the postoperative IOP reduction. Using XEN45 as unit of measurement, we transformed through equations the residual preoperative AHO in XEN45 equivalent in order to establish theoretical number of stents needed to reach the target IOP.

RESULTS

The mean preoperative washout IOP was 28.9 ± 5.4 mmHg, after 7 and 45 days the mean postoperative IOP was 12.6 ± 4.3 and 15.3 ± 4.4 mmHg, respectively (p < 0.001). A significant positive correlation was found between preoperative and postoperative IOP values. We obtained a mathematical relationship to estimate the theoretical number of XEN45 stents needed to reach the target IOP.

CONCLUSION

The basal IOP (after medical therapy washout) is a predictive factor for the surgical success after a XEN45 implant. Establishing the residual preoperative AHO it is possible to predict the theoretical number of stents to implant. A double XEN45 implant could be considered a possible further tool to reach the target IOP in patients with severe AHO deficiency.

摘要

目的

研究单根或双根 XEN45 凝胶支架(XEN45)植入青光眼眼中的理论流体动力学效应。

方法

对 63 例 63 只青光眼眼进行前瞻性非随机临床研究。将术前经过 14 天药物治疗洗脱后的眼内压(IOP)值与术后植入 XEN45 后第 7 天和第 45 天的术后 IOP 值进行相关性分析。设计了一个基于哈根-泊肃叶定律的数学模型,以评估青光眼眼中术后残余房水流出(AHO)功能与术后 IOP 降低的关系。我们用 XEN45 作为单位,通过方程将残余术前 AHO 转换为 XEN45 等效单位,以确定达到目标眼压所需的理论支架数量。

结果

平均术前洗脱 IOP 为 28.9 ± 5.4mmHg,术后第 7 天和第 45 天的平均术后 IOP 分别为 12.6 ± 4.3mmHg 和 15.3 ± 4.4mmHg(p<0.001)。术前和术后 IOP 值之间存在显著的正相关关系。我们获得了一种数学关系来估计达到目标眼压所需的理论 XEN45 支架数量。

结论

基础 IOP(药物治疗洗脱后)是 XEN45 植入术后手术成功的预测因素。确定残余术前 AHO 可以预测理论上需要植入的支架数量。在 AHO 严重缺乏的患者中,双根 XEN45 植入可能是达到目标眼压的另一种可能工具。

相似文献

1
Theoretic scientific rationale of double XEN 45 Gel Stent implant in severe glaucomatous ocular hypertension.双 XEN 45 凝胶支架植入治疗严重青光眼性高眼压的理论科学依据。
Int Ophthalmol. 2023 May;43(5):1629-1638. doi: 10.1007/s10792-022-02561-6. Epub 2022 Oct 29.
2
Glaucoma medical treatment as a predictor of XEN45 subconjunctival gel implant hypotensive efficacy.青光眼药物治疗作为XEN45结膜下凝胶植入物降压疗效的预测指标。
Graefes Arch Clin Exp Ophthalmol. 2023 Feb;261(2):521-533. doi: 10.1007/s00417-022-05810-7. Epub 2022 Aug 20.
3
Influence of Mitomycin C on the Therapeutic Success of Stand-Alone Xen45 Gel Stents and Its Combination with Cataract Surgery in Open-Angle Glaucoma Patients.丝裂霉素 C 对独立型 Xen45 凝胶支架治疗效果的影响及其与白内障手术联合应用于开角型青光眼患者的效果。
Klin Monbl Augenheilkd. 2021 Aug;238(8):861-867. doi: 10.1055/a-1384-1020. Epub 2021 May 17.
4
Mid-term surgical success after transscleral ab interno glaucoma gel stent implantation.经巩膜内路青光眼凝胶支架植入术后的中期手术成功率。
Acta Ophthalmol. 2024 Sep;102(6):e906-e914. doi: 10.1111/aos.16668. Epub 2024 Mar 13.
5
Effectiveness and safety of XEN45 implant over 12 months of follow-up: data from the XEN-Glaucoma Treatment Registry.XEN45 植入物在 12 个月随访期间的有效性和安全性:来自 XEN-青光眼治疗登记处的数据。
Eye (Lond). 2024 Jan;38(1):103-111. doi: 10.1038/s41433-023-02642-5. Epub 2023 Jul 6.
6
XEN Gel Stent Versus Nonpenetrating Deep Sclerectomy in Ocular Hypertension and Open Angle Glaucoma Patients.XEN 凝胶支架与非穿透性深层巩膜切除术治疗高眼压症和开角型青光眼患者的比较。
J Glaucoma. 2023 Jun 1;32(6):511-519. doi: 10.1097/IJG.0000000000002206. Epub 2023 Mar 7.
7
Real-World Retrospective Consecutive Study of Ab Interno XEN 45 Gel Stent Implant with Mitomycin C in Black and Afro-Latino Patients with Glaucoma: 40% Required Secondary Glaucoma Surgery at 1 Year.针对黑人及拉丁裔青光眼患者进行内路XEN 45凝胶支架植入联合丝裂霉素C的真实世界回顾性连续研究:1年时40%的患者需要进行继发性青光眼手术。
Middle East Afr J Ophthalmol. 2020 Jan 29;26(4):229-234. doi: 10.4103/meajo.MEAJO_126_19. eCollection 2019 Oct-Dec.
8
Two-year outcomes of minimally invasive XEN Gel Stent implantation in primary open-angle and pseudoexfoliation glaucoma.原发性开角型青光眼和假性剥脱性青光眼微创 XEN 凝胶支架植入的两年疗效。
Acta Ophthalmol. 2021 Jun;99(4):369-375. doi: 10.1111/aos.14627. Epub 2020 Sep 30.
9
Defining the role of ab externo Xen gel stent in glaucomatous eyes with prior failed surgical intervention.定义外路 Xen 凝胶支架在既往手术失败的青光眼眼中的作用。
Graefes Arch Clin Exp Ophthalmol. 2023 Mar;261(3):779-789. doi: 10.1007/s00417-022-05857-6. Epub 2022 Oct 22.
10
Matched case-control comparison of surgical success after XEN45 Gel Stent and PRESERFLO MicroShunt implantation in a Caucasian population.XEN45 Gel 支架和 PRESERFLO 微导管植入术后在白种人群中手术成功率的配对病例对照比较。
Clin Exp Ophthalmol. 2024 Sep-Oct;52(7):732-739. doi: 10.1111/ceo.14407. Epub 2024 Jun 6.

引用本文的文献

1
Double implantation of Xen 45 gel stent in primary open-angle glaucoma: a pilot study.原发性开角型青光眼 XEN45 凝胶支架双重植入:初步研究。
Int Ophthalmol. 2024 Jun 21;44(1):243. doi: 10.1007/s10792-024-03153-2.
2
Development and material characteristics of glaucoma surgical implants.青光眼手术植入物的研发与材料特性
Adv Ophthalmol Pract Res. 2023 Sep 23;3(4):171-179. doi: 10.1016/j.aopr.2023.09.001. eCollection 2023 Nov-Dec.

本文引用的文献

1
XEN glaucoma treatment system in the management of refractory glaucomas: a short review on trial data and potential role in clinical practice.XEN青光眼治疗系统在难治性青光眼治疗中的应用:试验数据及在临床实践中潜在作用的简要综述
Clin Ophthalmol. 2018 Apr 30;12:773-782. doi: 10.2147/OPTH.S146919. eCollection 2018.
2
Biocompatibility of a Novel Microfistula Implant in Nonprimate Mammals for the Surgical Treatment of Glaucoma.一种用于青光眼手术治疗的新型微瘘植入物在非灵长类哺乳动物中的生物相容性
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(8):3594-600. doi: 10.1167/iovs.16-19453.
3
Combined phacoemulsification and XEN45 surgery from a temporal approach and 2 incisions.
经颞侧入路及两个切口进行白内障超声乳化吸除术与XEN45手术联合操作。
Arch Soc Esp Oftalmol. 2016 Sep;91(9):415-21. doi: 10.1016/j.oftal.2016.02.006. Epub 2016 Mar 16.
4
Minimally invasive glaucoma surgery: current status and future prospects.微创青光眼手术:现状与未来展望。
Clin Ophthalmol. 2016 Jan 28;10:189-206. doi: 10.2147/OPTH.S80490. eCollection 2016.
5
Early Clinical Results of a Novel Ab Interno Gel Stent for the Surgical Treatment of Open-angle Glaucoma.一种用于开角型青光眼手术治疗的新型内路凝胶支架的早期临床结果
J Glaucoma. 2016 Jul;25(7):e691-6. doi: 10.1097/IJG.0000000000000352.
6
Phacoemulsification combined with a new ab interno gel stent to treat open-angle glaucoma: Pilot study.超声乳化联合新型内路凝胶支架治疗开角型青光眼:初步研究。
J Cataract Refract Surg. 2015 Sep;41(9):1905-9. doi: 10.1016/j.jcrs.2015.01.019. Epub 2015 Oct 23.
7
Fluid Dynamics of a Novel Micro-Fistula Implant for the Surgical Treatment of Glaucoma.用于青光眼手术治疗的新型微瘘植入物的流体动力学
Invest Ophthalmol Vis Sci. 2015 Jul;56(8):4789-95. doi: 10.1167/iovs.15-16625.
8
Ab interno approach to the subconjunctival space using a collagen glaucoma stent.使用胶原青光眼支架经结膜下间隙的内路入路。
J Cataract Refract Surg. 2014 Aug;40(8):1301-6. doi: 10.1016/j.jcrs.2014.01.032. Epub 2014 Jun 15.
9
Micro-invasive glaucoma surgery: current perspectives and future directions.微创青光眼手术:现状与未来方向。
Curr Opin Ophthalmol. 2012 Mar;23(2):96-104. doi: 10.1097/ICU.0b013e32834ff1e7.
10
Aqueous humor dynamics: a review.房水动力学:综述
Open Ophthalmol J. 2010 Sep 3;4:52-9. doi: 10.2174/1874364101004010052.